Drug Profile


Alternative Names: BIBR277; Kinzal; Kinzalmono; Micardis; Pritor; PritorPlus; Telma; YM086

Latest Information Update: 06 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim Pharma KG
  • Developer Abbott Laboratories; Astellas Pharma; Boehringer Ingelheim Pharma KG; GlaxoSmithKline; Glenmark Pharmaceuticals Ltd; Nippon Boehringer Ingelheim
  • Class Antihypertensives; Benzimidazoles; Benzoates; Small molecules
  • Mechanism of Action ACE inhibitors; Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Essential hypertension; Hypertension
  • No development reported Metabolic syndrome
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 30 Oct 2017 Nippon Boehringer Ingelheim and Astellas Pharma extend agreement related to the sales of telmisartan (Micardis® family) in Japan
  • 07 Jan 2016 Boehringer Ingelheim and Astellas Pharma extend agreement related to sale and co-promotion of telmisartan (Micardis® family) in Japan
  • 17 Jun 2015 Launched for Cardiovascular disorders (Prevention) in Iceland and Vietnam (PO) before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top